Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Morria Biopharmaceuticals has initiated of a randomized, placebo-controlled, double blind, Phase I tolerance study of its anti-inflammatory drug in 16 patients suffering from allergic rhinitis.
Subscribe to our email newsletter
This is Morria’s first human study in allergic rhinitis (AR). The anti-inflammatory drug, MRX-4 is nasally administered as a single dose either with or without an allergen challenge to determine tolerance. Results are expected by the end of the fourth quarter of 2007.
Yuval Cohen, president of Morria, said: “We are excited to be taking this significant step toward introducing a potentially safer, more effective and more affordable treatment option to the multibillion-dollar AR market.”
Peter Barnes, a professor at the National Heart & Lung Institute at Imperial College in London and Morria scientific advisory board member, said: “There is a real and urgent need for novel, non-steroidal treatments for inflammatory diseases such as allergic rhinitis. Morria’s drug platform could potentially offer such an alternative.”